WallStreetZenWallStreetZen

NASDAQ: RXRX
Recursion Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RXRX

Based on 2 analysts offering 12 month price targets for Recursion Pharmaceuticals Inc

Min Forecast
$8.00+123.46%
Avg Forecast
$9.50+165.36%
Max Forecast
$11.00+207.26%

Should I buy or sell RXRX stock?

Based on 2 analysts offering ratings for Recursion Pharmaceuticals Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RXRX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RXRX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their RXRX stock forecasts and price targets.

RXRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-17
lockedlocked$00.00+00.00%2025-09-11

1 of 1

Forecast return on equity

Is RXRX forecast to generate an efficient return?

Company
-47.68%
Industry
275.71%
Market
238.37%
RXRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RXRX forecast to generate an efficient return on assets?

Company
-35.67%
Industry
114.68%
RXRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RXRX earnings per share forecast

What is RXRX's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
-$1.16
Avg 2 year Forecast
-$1.00
Avg 3 year Forecast
-$1.10

RXRX revenue forecast

What is RXRX's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$84.4M+93.08%
Avg 2 year Forecast
$159.1M+264.21%
Avg 3 year Forecast
$173.7M+297.61%
RXRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RXRX revenue growth forecast

How is RXRX forecast to perform vs Biotechnology companies and vs the US market?

Company
64.81%
Industry
119.45%
Market
23.3%
RXRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RXRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RXRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RXRX$3.58$9.50+165.36%Strong Buy
AUPH$14.31$17.33+21.13%Buy
SNDX$21.14$99.11+368.83%Strong Buy
SRPT$17.40$22.75+30.75%Hold
STOK$31.89$35.00+9.75%Strong Buy
View Top Biotech Stocks

Recursion Pharmaceuticals Stock Forecast FAQ

Is Recursion Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: RXRX) stock is to Strong Buy RXRX stock.

Out of 2 analysts, 1 (50%) are recommending RXRX as a Strong Buy, 1 (50%) are recommending RXRX as a Buy, 0 (0%) are recommending RXRX as a Hold, 0 (0%) are recommending RXRX as a Sell, and 0 (0%) are recommending RXRX as a Strong Sell.

If you're new to stock investing, here's how to buy Recursion Pharmaceuticals stock.

What is RXRX's earnings growth forecast for 2026-2028?

(NASDAQ: RXRX) Recursion Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 61.98%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.85%.

Recursion Pharmaceuticals's earnings in 2026 is -$715,543,000.On average, 12 Wall Street analysts forecast RXRX's earnings for 2026 to be -$603,113,009, with the lowest RXRX earnings forecast at -$668,401,658, and the highest RXRX earnings forecast at -$344,405,434. On average, 8 Wall Street analysts forecast RXRX's earnings for 2027 to be -$523,090,159, with the lowest RXRX earnings forecast at -$663,299,355, and the highest RXRX earnings forecast at -$278,804,399.

In 2028, RXRX is forecast to generate -$573,540,479 in earnings, with the lowest earnings forecast at -$551,048,695 and the highest earnings forecast at -$590,409,316.

What is RXRX's revenue growth forecast for 2026-2028?

(NASDAQ: RXRX) Recursion Pharmaceuticals's forecast annual revenue growth rate of 64.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 119.45%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.3%.

Recursion Pharmaceuticals's revenue in 2026 is $43,689,000.On average, 12 Wall Street analysts forecast RXRX's revenue for 2026 to be $43,918,331,094, with the lowest RXRX revenue forecast at $31,175,590,341, and the highest RXRX revenue forecast at $60,680,957,501. On average, 8 Wall Street analysts forecast RXRX's revenue for 2027 to be $82,844,735,800, with the lowest RXRX revenue forecast at $41,545,760,323, and the highest RXRX revenue forecast at $174,936,093,696.

In 2028, RXRX is forecast to generate $90,440,919,155 in revenue, with the lowest revenue forecast at $86,890,132,967 and the highest revenue forecast at $93,101,405,580.

What is RXRX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RXRX) forecast ROA is -35.67%, which is lower than the forecast US Biotechnology industry average of 114.68%.

What is RXRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year RXRX price target, the average RXRX price target is $9.50, with the highest RXRX stock price forecast at $11.00 and the lowest RXRX stock price forecast at $8.00.

On average, Wall Street analysts predict that Recursion Pharmaceuticals's share price could reach $9.50 by Dec 17, 2026. The average Recursion Pharmaceuticals stock price prediction forecasts a potential upside of 165.36% from the current RXRX share price of $3.58.

What is RXRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RXRX) Recursion Pharmaceuticals's current Earnings Per Share (EPS) is -$1.84. On average, analysts forecast that RXRX's EPS will be -$1.16 for 2026, with the lowest EPS forecast at -$1.28, and the highest EPS forecast at -$0.66. On average, analysts forecast that RXRX's EPS will be -$1.00 for 2027, with the lowest EPS forecast at -$1.27, and the highest EPS forecast at -$0.54. In 2028, RXRX's EPS is forecast to hit -$1.10 (min: -$1.06, max: -$1.13).

What is RXRX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RXRX) forecast ROE is -47.68%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.